Medicenna Therapeutics Corp. Overview
Pro stress-test →Medicenna Therapeutics is a clinical-stage immunotherapy company focused on developing Superkines targeting cancer and autoimmune diseases. The company's lead candidate MDNA11 has demonstrated best-in-class IL-2 super agonist potential, with 50% overall response rate in second-line/third-line cancer settings and 42% when used as next treatment after immunotherapy checkpoint failure.
Strategic Profile
Pro stress-test →Medicenna positions itself as a pre-eminent leader in best and first-in-class superkine-based therapeutics. The company is advancing MDNA113, a tumor-targeted bi-functional conditionally activated anti-PD1-IL-2, towards IND-enabling studies with plans to commence a first-in-human trial in H2 2026. The company also maintains MDNA55, an Empowered Superkine for recurrent glioblastoma treatment, which is a fusion of interleukin-4 fused to Pseudomonas exotoxin.
Competitive Landscape
Pro stress-test →Medicenna competes in the immuno-oncology space against established checkpoint inhibitors (Merck's Keytruda, Bristol Myers Squibb's Opdivo, Roche's Tecentriq) and emerging IL-2 therapeutic candidates. The company differentiates through its Superkine platform enabling engineered cytokines with improved safety and efficacy profiles. MDNA11's clinical data positioning as a best-in-class IL-2 agonist for patients with checkpoint inhibitor-resistant tumors addresses a significant unmet need in advanced cancer.
Industry Context
Medicenna Therapeutics Corp. operates in Cancer immunotherapy — IL-2 super agonists.
Key facts
Founded: 2014 · Headquarters: Houston, US · Employees: Unknown · Revenue: N/A · Market cap: $21.3M